EDWARD OLADIPO: Open Payments
NPI 1821795311 · NORTH BRUNSWICK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$678 in 34 payments from 9 companies in 2025. Trend: 2023 $189 · 2024 $47 · 2025 $678
Food & beverage: $678
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $257 |
| Neurocrine BioSciences, Inc. | 6 | $129 |
| Janssen Pharmaceuticals, Inc | 4 | $75 |
| Alkermes, Inc. | 3 | $50 |
| Lundbeck LLC | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
Products named: VRAYLAR, INGREZZA, REXULTI, INVEGA SUSTENNA, ARISTADA, CAPLYTA, SPRAVATO, AUSTEDO XR.
Industry payments across NJ — which companies pay providers there.
